The restructuring is aimed at freeing up resources so the firm can advance its EBV-positive peripheral T-cell lymphoma drug toward the market.
SRP-5051 is designed to bind to exon 51 of dystrophin pre-mRNA, resulting in exclusion of this exon during mRNA processing in patients with genetic mutations amenable to exon 51 skipping. With this ...
The company will use the proceeds to develop its gene therapies for eye disorders and for general corporate expenses.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback